Conclusion
Our study based on a large cohort of patients affected by major
depressive disorder suggests that mirtazapine treatment may be
associated with the increased risk of developing hypothyroxinemia.
Further investigations are needed to clarify the clinical relevance of
this association and its long-term impact on the treated
patients.